Abstract
We aimed to explore the effect of circGFRA1 on the progression of hepatocellular carcinoma (HCC) and its underlying mechanism. First, quantitative Real Time-Polymerase Chain Reaction (qRT-PCR) was conducted to detect the level of circGFRA1 in HCC tissues and cells. Survival analysis was applied to detect the effect of highly expressed circGFRA1 on the prognosis of HCC patients. Subsequently, circGFRA1 level was silenced in HCC cells, and proliferative, migration and angiogenesis activity of HCC cells was examined using Cell Counting Kit-8 (CCK-8), transwell test, and angiogenesis experiment. Then, we predicted the binding target of circGFRA1 through the bioinformatics website, and verified it through qRT-PCR and Dual-Luciferase reporter assay. Lastly, the interaction between them was verified through a series of in vitro experiments. qRT-PCR analysis showed that circGFRA1 was abnormally highly expressed in HCC tissues and HCC cells, and the high expression of circGFRA1 may lead to poor prognosis in patients with HCC. After transfecting si-circGFRA1 in HCC cells, CCK-8 and transwell experiments showed that the proliferative ability and migration of HCC cells were inhibited. Moreover, angiogenesis experiments showed that the knockdown of circGFRA1 can inhibit the blood vessels replenishment of HCC cells. The bioinformatics website suggested that miR-149 may be able to bind circGFRA1. MiR-149 was upregulated by the knockdown of circGFRA1 in HCC cells. Pearson analysis suggested that the expression levels of the two genes were negatively correlated. Dual-Luciferase reporter assay further indicated that circGFRA1 can bind to miR-149. Reverse experiment showed that the knockdown of miR-149 can partially restore the inhibited proliferative, migration, and angiogenesis activity of HCC cells caused by circGFRA1 knockdown. CircGFRA1 is highly expressed in HCC and its level is negatively correlated with miR-149 expression. CircGFRA1 can promote the proliferative, migration and angiogenic activity of HCC by binding miR-149.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: European review for medical and pharmacological sciences
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.